All In Biotech

Drug Trial Radar · NCT06241118

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 464 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

464

Actual

Start

Feb 29, 2024

Primary completion

Sep 30, 2027

Study completion Sep 29, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 \[RIVER-AD\] study).

Conditions

  • Dermatitis Atopic

Interventions

  • AmlitelimabDrug

    Pharmaceutical form: Injection solution Route of administration: Subcutaneous

  • PlaceboDrug

    Pharmaceutical form: Injection solution Route of administration: Subcutaneous

  • Topical corticosteroidsDrug

    Pharmaceutical form: Various Topical formulation Route of administration: Topical

  • Topical tacrolimus or pimecrolimusDrug

    Pharmaceutical form: Various Topical formulation Route of administration: Topical

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 36Time frame: Week 36
  2. EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI75) at Week 36Time frame: Week 36
  3. US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 36Time frame: Week 36

Locations

154 sites in 22 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham- Site Number : 8401267

    Birmingham, Alabama

  • Center for Dermatology and Plastic Surgery- Site Number : 8401119

    Scottsdale, Arizona

  • Arkansas Dermatology - North Little Rock- Site Number : 8401244

    North Little Rock, Arkansas

  • Exalt Clinical Research- Site Number : 8401344

    Chula Vista, California

  • Encino Research Center- Site Number : 8401042

    Encino, California

  • Center for Dermatology Clinical Research- Site Number : 8401018

    Fremont, California

  • Long Beach Clinical Trials- Site Number : 8401188

    Long Beach, California

  • Dermatology Research Associates- Site Number : 8401092

    Los Angeles, California

  • LA Universal Research Center- Site Number : 8401064

    Los Angeles, California

  • University Dermatology Trials- Site Number : 8401339

    Newport Beach, California

  • Rady Children's Hospital- Site Number : 8401291

    San Diego, California

  • Therapeutics Clinical Research- Site Number : 8401283

    San Diego, California

  • Paradigm Clinical Research - Wheat Ridge- Site Number : 8401245

    Wheat Ridge, Colorado

  • Encore Medical Research of Boynton Beach- Site Number : 8401030

    Boynton Beach, Florida

  • St. Jude Clinical Research- Site Number : 8401287

    Doral, Florida

  • Apex Clinical Research - Jacksonville- Site Number : 8401332

    Jacksonville, Florida

  • Clever Medical Research- Site Number : 8401160

    Miami, Florida

  • Future Care Solution - Miami- Site Number : 8401340

    Miami, Florida

  • Global Clinical Professionals (GCP)- Site Number : 8401045

    St. Petersburg, Florida

  • Avita Clinical Research- Site Number : 8401073

    Tampa, Florida

  • Northwestern University- Site Number : 8401285

    Chicago, Illinois

  • NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8401038

    Skokie, Illinois

  • Dawes Fretzin Clinical Research- Site Number : 8401015

    Indianapolis, Indiana

  • Equity Medical - Bowling Green- Site Number : 8401296

    Bowling Green, Kentucky

  • Tandem Clinical Research - Metairie- Site Number : 8401187

    Metairie, Louisiana

  • University of Michigan Health System - Ann Arbor- Site Number : 8401290

    Ann Arbor, Michigan

  • MI Skin Center- Site Number : 8401307

    Northville, Michigan

  • Schweiger Dermatology Group - East Windsor- Site Number : 8401338

    East Windsor, New Jersey

  • The University of New Mexico- Site Number : 8401263

    Albuquerque, New Mexico

  • Sadick Research Group - New York - Park Avenue- Site Number : 8401050

    New York, New York

  • Equity Medical (LLC)- Site Number : 8401239

    The Bronx, New York

  • Cincinnati Children's Hospital Medical Center- Site Number : 8401279

    Cincinnati, Ohio

  • Oregon Health & Science University (OHSU)- Site Number : 8401247

    Portland, Oregon

  • Paddington Testing Company- Site Number : 8401041

    Philadelphia, Pennsylvania

  • Clinical Research of Philadelphia- Site Number : 8401193

    Philadelphia, Pennsylvania

  • Medical University of South Carolina - Charleston - Jonathan Lucas Street- Site Number : 8401282

    Charleston, South Carolina

  • Arlington Research Center- Site Number : 8401248

    Arlington, Texas

  • McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8401288

    Bellaire, Texas

  • Reveal Research Institute - Dallas- Site Number : 8401219

    Dallas, Texas

  • Virginia Dermatology & Skin Cancer Center- Site Number : 8401047

    Norfolk, Virginia

Showing 40 of 154 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.